Latest news
Weekly Recap: XPORT-EC-042 misses PFS endpoint and SENTRY sNDA reports SVR35 - TradingViewTradingView · Mon, 03 Aug 2026 11:33:04 GMTKaryopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sat, 01 Aug 2026 06:33:05 GMTSelinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 14:37:53 GMTXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 14:00:00 GMTKPTI Stock Craters As Trial Failure And Legal Scrutiny Hit - StocksToTradeStocksToTrade · Fri, 31 Jul 2026 13:17:00 GMTKaryopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA - TradingViewTradingView · Fri, 31 Jul 2026 12:33:01 GMTKaryopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move - TradingViewTradingView · Fri, 31 Jul 2026 05:25:00 GMTSelinexor Misses Primary Endpoint in Endometrial Cancer Trial - MPR - Medical Professionals ReferenceMedical Professionals Reference · Fri, 31 Jul 2026 04:00:00 GMT